Major indices were firmly in the red early on Friday as Donald Trump's tariff-driven market rout looked set to continue for ...

The latest CNBC CFO Council Survey found that 60% of CFOs expect a U.S. recession later in 2025. Another 15% predict a ...

Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

The Nasdaq 100 (NDX) index just had the worst quarterly performance in the first quarter of 2025 in nearly three years. The tech-skewed index, which features heavyweights like Apple (AAPL) -11.3% YTD, ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...